- Home
- RMCF vs BIAF Comparison
RMCF vs BIAF Comparison
Compare RMCF & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMCF
- BIAF
- Stock Information
- Founded
- RMCF 1981
- BIAF 2014
- Country
- RMCF United States
- BIAF United States
- Employees
- RMCF N/A
- BIAF N/A
- Industry
- RMCF Specialty Foods
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- RMCF Consumer Staples
- BIAF Health Care
- Exchange
- RMCF Nasdaq
- BIAF Nasdaq
- Market Cap
- RMCF 13.3M
- BIAF 12.2M
- IPO Year
- RMCF N/A
- BIAF 2022
- Fundamental
- Price
- RMCF $1.16
- BIAF $0.21
- Analyst Decision
- RMCF
- BIAF Hold
- Analyst Count
- RMCF 0
- BIAF 1
- Target Price
- RMCF N/A
- BIAF N/A
- AVG Volume (30 Days)
- RMCF 8.9K
- BIAF 799.6K
- Earning Date
- RMCF 06-12-2025
- BIAF 05-23-2025
- Dividend Yield
- RMCF N/A
- BIAF N/A
- EPS Growth
- RMCF N/A
- BIAF N/A
- EPS
- RMCF N/A
- BIAF N/A
- Revenue
- RMCF $27,939,687.00
- BIAF $9,362,022.00
- Revenue This Year
- RMCF N/A
- BIAF N/A
- Revenue Next Year
- RMCF N/A
- BIAF $19.99
- P/E Ratio
- RMCF N/A
- BIAF N/A
- Revenue Growth
- RMCF N/A
- BIAF 269.68
- 52 Week Low
- RMCF $1.12
- BIAF $0.16
- 52 Week High
- RMCF $3.59
- BIAF $2.99
- Technical
- Relative Strength Index (RSI)
- RMCF 37.52
- BIAF 32.86
- Support Level
- RMCF $1.21
- BIAF $0.19
- Resistance Level
- RMCF $1.28
- BIAF $0.24
- Average True Range (ATR)
- RMCF 0.07
- BIAF 0.04
- MACD
- RMCF -0.01
- BIAF -0.02
- Stochastic Oscillator
- RMCF 0.00
- BIAF 13.80
About RMCF Rocky Mountain Chocolate Factory Inc.
Rocky Mountain Chocolate Factory Inc operates as a manufacturer of chocolate candies and confectionery products. The business activity of the firm functions through Franchising, Manufacturing, Retail Stores, U-Swirl Operations, and Other t. The products of the company include varieties of Clusters, Caramels, Creams, Toffees, Mints, and Truffles.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.